Vaccines in the public eye

Nature Medicine

Volumn 11, Issue 4 SUPPL., 2005, Pages

  Ritvo, Paul ^a,b   Wilson, Kumanan ^b   Willms, Dennis ^c   Upshur, Ross ^b,d  

^a YORK UNIVERSITY   (Canada)

^b TORONTO GENERAL HOSPITAL   (Canada)

^c MCMASTER UNIVERSITY   (Canada)

^d SUNNYBROOK RESEARCH INSTITUTE   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

HEPATITIS B VACCINE; MEASLES MUMPS RUBELLA VACCINE; SMALLPOX VACCINE; VACCINE;

AVIAN INFLUENZA; CANADA; DIPHTHERIA; ETHICS; FRANCE; HEALTH CARE POLICY; HEPATITIS B; HERD IMMUNITY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNIZATION; INFECTION; MANAGED CARE ORGANIZATION; MEASLES; MORTALITY; MOZAMBIQUE; MULTIPLE SCLEROSIS; PERTUSSIS; POLIOMYELITIS; PREVENTIVE HEALTH SERVICE; PRIORITY JOURNAL; PUBLIC OPINION; REVIEW; SEVERE ACUTE RESPIRATORY SYNDROME; SMALLPOX; SYSTEMATIC REVIEW; UNITED KINGDOM; UNITED NATIONS; UNITED STATES; WART VIRUS; WORLD HEALTH ORGANIZATION;

BIOETHICAL ISSUES; DISEASE OUTBREAKS; HEALTH POLICY; HEALTH PROMOTION; HUMANS; INTERNATIONAL COOPERATION; PATIENT COMPLIANCE; PUBLIC SECTOR; VACCINATION; VACCINES; WORLD HEALTH;

AVES; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN PAPILLOMAVIRUS TYPES; VARIOLA VIRUS;

EID: 17644417771     PISSN: 10788956     EISSN: None     Source Type: Journal    
DOI: 10.1038/nm1220     Document Type: Review

References (57)

1. Diamond, J. Guns, Germs and Steel (W.W. Norton & Company, New York, 1999).
2. Potter, C.W. in Textbook of Influenza (eds Nicholson, K.G., Webster, R.G. & Hay, A.J.) 3-18 (Blackwell Science, Oxford, 1998).
3. Donnelly, C.A. et al. Lancet Infect. Dis. 4, 672-683 (2004).
4. World Health Organization. Summary table of SARS cases by country, 1 November 2002 - 7 August 2003 〈http://www.who.int/csr/sars/country/en/ country2003_08_15.pdf〉 (2003).
5. Knobler, S.L., Mack, A., Mahmoud, A. & Lemon, S.M. (eds). The threat of pandemic influenza: are we ready? Workshop summary report by the Board on Global Health, Institute of Medicine. (National Academies Press, Washington, DC, 2004).
6. Weiss, R.A. & McMichael, A.J. Nat. Med. 10, S70-S76 (2004).
7. Kremer, M. in Global Public Goods Financing: New Tools for New Challenges, A Policy Dialogue (eds Kaul, I., Goulven, K. & Schnupf, M.) 37-42 (UNDP/ODS, New York, 2002).
8. Kremer, M. & Glennerster, R. A World Bank vaccine commitment. Brookings Institution Policy Brief #57 〈http://www.brookings.edu/comm/ policybriefs/pb57.htm〉 (2000).
9. Plotkin, S.L. & Plotkin, S.A. in Vaccines (eds Plotkin; S.A. & Orenstein W.A.) 1-11 (Saunders, Philadelphia, 1999).
10. Slovic, P. Science 236, 280 (1987)
11. Greenberg, S. South. Med. J. 93, 763-767 (2000).
12. Hennock, E.P. Soc. Hist. Med. 11, 49-71 (1998).
13. Gellin, B.G., Maibach, E.W. & Marcuse, E.K. Pediatrics 106, 1097-1102 (2000).
14. Mieczkowski, T.A. & Wilson, S.A. Vaccine 18, 1383-1392 (2002).
15. Liau, A. & Zimet, G.D. AIDS Care 13, 643-650 (2001)
16. Liau, A. & Zimet, G.D. Int. J. STD AIDS 11, 445-450 (2000)
17. Zimet, G.D., Blythe, M.J. & Fortenberry, J.D. Int. J. STD AIDS 11, 143-149 (2000).
18. Honkanen, P.O., Keistinen, T. & Kivela, S.L. Public Health 110, 163-168 (1996).
19. Zimet, G.D., Fortenberry, J.D. & Blythe, M.J. J. Pediatr. Psychol. 24, 67-75 (1999).
20. Webb, P.M., Zimet, G.D., Mays, R. & Fortenberry, J.D. J. Adoles. Health 25, 320-322 (1999).
21. Liau, A., Zimet, G.D. & Fortenberry, J.D. Sex Transm. Dis. 25, 76-81 (1998).
22. Nichol, K.L. & Zimmerman, R. Arch. Intern. Med. 161, 2702-2708 (2001).
23. Nichol, K.L., Lofgren, R.P. & Gapinski, J. Arch. Intern. Med. 152, 106-10 (1992).
24. McPhillips, H.A., Davis, R.L., Marcuse, E.K. & Taylor, J.A. Arch. Pediatr. Adolesc. Med. 155: 1051-1056 (2001).
25. Fiebach, N.H. & Viscoli, C.M. Am. J. Med. 91, 393-400 (1991).
26. Mezaros J.R. et al. J. Clin. Epidemiol. 49, 697-703 (1996).
27. Ritvo, P. et al. J. Immune Based Ther. Vaccines 1, 3 (2003).
28. Abraham, J. Lancet 360, 1498-1502 (2002).
29. Keller-Stanislawski, B. Vaccine 20, S45-S46 (2002).
30. Hernan, M.A., Jick, S.S., Olek, M.J. & Jick, H. Neurology 63, 838-842 (2004).
31. Immunization Safety Committee. Immunization safety review: hepatitis B vaccine and demyelinating neurological disorders (National Academy Press, Washington, DC, 2002).
32. DeStefano, F. et al. Arch. Neurol. 60, 504-509 (2003).
33. Ascherio, A. et al. N. Engl. J. Med. 344, 327-332 (2001).
34. Confavreux, C., Suissa, S., Saddier, P., Bourdes, B. & Vukusic, S. N. Engl. J. Med. 344, 319-326 (2001).
35. Sadovnick, A.D. & Scheifele, D.W. Lancet 355, 549-550 (2000).
36. World Health Organization Global Advisory Committee on Vaccine Safety. Response to the paper by MA Hernán and others in Neurology 14th September 2004 issue entitled "Recombinant Hepatitis B Vaccine and the Risk of Multiple Sclerosis" 〈http://www.who.int/vaccine_safety/topics/ hepatitisb/multiple_sclerosis/sep_04/en/〉 (2004).
37. Levy-Bruhl, D., Desenclos, J.C., Rebiere, I. & Drucker, J. Vaccine 20, 2065-2071 (2002).
38. Touze, E., Gout, O., Verdier-Taillefer, M.H., Lyon-Caen, D. & Alperovitch, A. Rev. Neurol. 152, 242-246 (2000).
39. Touzé, E., Fourrier, A., Rue-Fenouche, C., Rondé-Ousteau, V., Jeantaud, I. & Bégaud, B. Neuroepidemiology 21, 180-186 (2002).
40. Sturkenboom, M.C.J.M. et al. Pharmacoepidemiol. Drug Saf. 8, S170-S171 (1999).
41. Cage, S. WHO: Islamic state in Nigeria will resume polio vaccinations in early July. Associated Press 30 June 2004.
42. Qadir, A. India gears up for last mile of polio eradication but poor shun vaccine drops in eastern state. Associated Press 28 August 2004.
43. Renn, O. Risk communication and social amplification of risk. In Communicating Risks to the Public: International Perspectives (eds. Kasperson, RE. & Stallen, P.M.) (Kluwer, Amsterdam, 1991).
44. Powell, D. & Leiss, W. Mad Cows and Mother's Milk: The Peril of Poor Risk Communication (McGill-Queen's University Press, Montreal, 1997).
45. UK Department of Health. Statistical Bulletin: NHS Immunization Statistics 2003-04 (UK Department of Health, London, 2004).
46. Wakefield, A.J. et al. Lancet 351, 637-641 (1998).
47. Murch, S.H., et al. Lancet 363(9411), 750 (2004).
48. Ward, L. Minister outlines steps to boost image of MMR jabs. The Guardian. 21 February 2002.
49. Jansen, V.A. et al. Science 301, 804 (2003).
50. Krahn, M. et al. Vaccine 23, 1549-1558 (2005).
51. Kremer, A. A Purchase Commitment for Vaccines, in Global Public Goods Financing: New Tools for New Challenges, A Policy Dialogue, (ed. Kaul, I., le Goulven, K. & Schnupf, M.) 37-42 (UNDP/ODS, New York, 2002).
52. Muraskin, W., Hotez, P. & Sachs, J. Vaccines for developing economies - who will pay? The Albert Sabin Vaccine Institute Colloquium at Cold Spring Harbor (The Albert B. Sabin Vaccine Institute, New Canaan, Connecticut, 2001).
53. Horton, R. Lancet 364, 2071-2074 (2004).
54. Hirschler, B. Chirac calls for global tax to fight AIDS. The Toronto Star. January 27, 2005.
55. Ungchusak, K. et al. N. Eng. J. Med. 352, 333-3640 (2005).
56. Alonso, P.L. et al. Lancet 364, 1411-1420 (2004).
57. Harper, D.M. et al. Lancet 364, 1757-1765 (2004).